

DAY 1 AGENDA

*Denotes Remote Participation

8:00 AM	Registration and Breakfast	
9:00 AM	Introductory Remarks and Program Overview	
9:00 AM	Welcome, Program Overview, and Acknowledgements	<i>Edyth Dwyer, Forum for Collaborative Research</i>
9:05 AM	Opening Remarks	<i>Veronica Miller, Forum for Collaborative Research Becky Taub, Madrigal Pharmaceuticals</i>
9:15 AM	Session I: Patient Engagement Working Group	
	Moderators: Becky Taub, Madrigal Pharmaceuticals	
9:15 AM	The Dr. Stephen Harrison Patient Advocacy Fellowship: Overview	<i>Elena Samsonova, Fatty Liver Foundation</i>
9:20 AM	Patient Engagement in Drug Development: Leading Through Example (PEDDL)- Platform Demonstration	<i>Becca Freed*, Edyth Dwyer, Forum for Collaborative Research Henry Chang, Fatty Liver Foundation Michael Betel*, Fatty Liver Alliance Rosemarie Sellati*, Regeneron</i>
9:30 AM	Open Discussion	<i>All Meeting Participants</i>
9:40 AM	Session II: Industry Rapid Fire Updates	
	Moderators: Veronica Miller & Mark Hartman, Forum for Collaborative Research	
9:40 AM	Company Updates	
11:00 AM	Coffee Break	
11:30 AM	Session III: Liver Forum Working Group Updates	
	Moderators: Veronica Miller, Forum for Collaborative Research; Dean Hum, Genfit	
11:30 AM	Non-MASH Liver Forum Program Updates: PCLD, PSC, ACLF	<i>Richard Moreau*, EF CLIF Jacqueline O'Leary*, Dallas VA Medical Center Pamela Vig*, Mirum Pharmaceuticals</i>
11:45 AM	Pediatric MASH Working Group	<i>Bryan Rudolph, Boehringer Ingelheim</i>
11:55 AM	Session IV: Update on Phase 3 Trials and Beyond	
	Moderators: Henry Chang, Fatty Liver Foundation; Scott Harris, Middleburg Consultants	
11:55 AM	SYNERGY NASH Design and Goals	<i>Arun Sanyal, Virginia Commonwealth University</i>
12:05 PM	Resmetirom's MAESTRO Phase 3 Program	<i>Dave Soergel, Madrigal Pharmaceuticals</i>
12:15 PM	Novo Nordisk Update	<i>Michelle Long, Novo Nordisk</i>
12:25 PM	Open Discussion	<i>All Meeting Participants</i>
1:00 PM	Lunch	
2:00 PM	Session V: Towards Validated Surrogate Endpoints: Data Science	
	Moderators: Veronica Miller, Forum for Collaborative Research; Becky Taub, Madrigal Pharmaceuticals	
2:00 PM	Placebo Arm Database Project Update	<i>Margot Yann, Forum for Collaborative Research</i>
2:10 PM	Data Overview	<i>Veronica Miller, Forum for Collaborative Research</i>
2:20 PM	VCTE Prognosis Study Group	<i>Vincent Wong*, The Chinese University of Hong Kong</i>
2:25 PM	Global NIT Study Group	<i>Georg Semmler*, Medical University of Vienna</i>
2:30 PM	Panel Discussion	<i>Peter Mesenbrink, Novartis Alejandro Schuler, University of California, Berkeley Jeffrey Siegel, U.S. Food and Drug Administration</i>
3:40 PM	Coffee Break	
4:10 PM	Session VI: Towards Validated Surrogate Endpoints: Biomarker Science	
	Moderators: Veronica Miller, Forum for Collaborative Research; Roberto Calle, FNIH Biomarkers Consortium	
4:10 PM	RLSE and Validated Surrogate Endpoints	<i>Roberto Calle, FNIH Biomarkers Consortium</i>
4:20 PM	RLSE Development: Brief Experience from Rare Kidney Disease	<i>Dave Soergel, Madrigal Pharmaceuticals</i>
4:35 PM	Biomarkers in Noncirrhotic MASH: What Is Our North Star?	<i>Suneil Hosmane, Madrigal Pharmaceuticals</i>
4:45 PM	Panel Discussion	<i>Lisa Boyette, Eli Lilly and Company Céline Fournier, Echosens Michelle Long, Novo Nordisk Peter Mesenbrink, Novartis Arun Sanyal, Virginia Commonwealth University Alejandro Schuler, University of California, Berkeley Jeffrey Siegel, U.S. Food and Drug Administration</i>

6:05 PM	Session VII: Collaborative Path Forward	
6:05 PM	Collaborative Path Forward	<i>Veronica Miller, Forum for Collaborative Research Arun Sanyal, Virginia Commonwealth University Becky Taub, Madrigal Pharmaceuticals</i>
6:20 PM	Adjourn & Evening Reception	

DAY 2 AGENDA

*Denotes Remote Participation

8:00 AM	Registration and Breakfast	
9:00 AM	Session VIII: Stretch Exercise	
	Moderators: Veronica Miller, Forum for Collaborative Research; Manu Chakravarthy, Genentech/Roche	
9:00 AM	The Reinvention of Medicine with AI...and What That Means for the Life Sciences	<i>Nick Gossen, Dandelion Health Ziad Obermeyer*, University of California, Berkeley</i>
9:35 AM	Open Discussion	<i>All Meeting Participants</i>
10:00 AM	Coffee Break	
10:30 AM	Session IX: Definition of the Progression to Cirrhosis and Decompensated Cirrhosis	
	Moderators: Veronica Miller, Forum for Collaborative Research; Roberto Calle, FNIH Biomarkers Consortium	
10:30 AM	Progression to Cirrhosis- a Critical Analysis of the Endpoint	<i>Arun Sanyal, Virginia Commonwealth University</i>
10:45 AM	Endpoints in MASH Cirrhosis Trials	<i>Becky Taub, Madrigal Pharmaceuticals</i>
11:00 AM	Panel Discussion	<i>Paolo Angeli*, University of Padova Wayne Eskridge*, Fatty Liver Foundation Reshma Shringarpure, Akero Therapeutics/Novo Nordisk</i>
11:45 AM	Session X: What's Next?	
11:45 AM	Wrap Up	<i>Veronica Miller, Forum for Collaborative Research Arun Sanyal, Virginia Commonwealth University Becky Taub, Madrigal Pharmaceuticals</i>
12:00 PM	Adjourn & Lunch	